

Embargo until 5:40 p.m. (Belgian time) – April 17, 2007

IBt and IBA sign a distribution agreement

IBt continues to expand its product range in field of radiation oncology

Seneffe and Louvain-la-Neuve, Belgium, April 17, 2007.

International Brachytherapy s.a. ("IBTB" on Euronext, Brussels) announces that it has signed a distribution agreement with IBA (Ion Beam Applications S.A.).

The distribution agreement grants IBt the exclusive distribution rights for Visicoil™ for United Kingdom, Ireland, Belgium, Luxembourg, The Netherlands and France and a non-exclusive distribution right for Austria. Other countries can potentially be added at a later stage.

Visicoil™ is a gold marker being used in Image Guided Radiation Therapy (IGRT). Visicoil™ can be implanted in cancer tissue allowing more accurate target identification and precise patient positioning during external beam radiation therapy. Thanks to Visicoil™, higher doses can be delivered to the tumour without increasing the dose delivered to the surrounding healthy tissue.

IGRT is rapidly gaining interest in the radiation oncology community based on proven scientific results. It is expected to become the gold standard for treatment in external beam radiation therapy especially for organs subject to position movement such as prostate, lung, pancreas, etc...

The distribution of Visicoil™ is another step forward in IBt's strategy to complement its product offering towards the radiation oncology community.

IBt, International Brachytherapy s.a., a Belgian company listed on Euronext, designs, manufactures and markets worldwide a complete range of radiotherapy implants used in brachytherapy. Brachytherapy is a medical technology that consists of placing implants containing radio isotopes within the cancer tissue. Precision-dosed local radiation from the implants destroys the cancerous cells. The primary application of brachytherapy today is the treatment of localized prostate cancer..

IBA (Ion Beam Applications S.A.: Reuters IOBA.BR and Bloomberg IBAB.BB) delivers solutions of a unique precision in the fields of cancer diagnosis and therapy. The company also offers sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT, is integrated into the NextEconomy market segment and belongs to the BelMid index. Website: <http://www.iba-worldwide.com>.

Contacts IBt:

| | |
|--|-------------------------|
| Serge Lamisse, François Blondel | Managing Directors |
| Laurence Goemaere | Marketing Communication |
| Phone: +32-64- 520 811 | |
| Internet: www.ibt.be | |

Contact IBA:

Paul-Emmanuel Goethals
Director, Corporate Business Development & Investor Relations
Phone: +32 10 47 58 16
paul-emmanuel.goethals@iba-group.com